Versant Ventures is a leading healthcare-focused venture capital firm specializing in early-stage investment in medical devices, biotechnology and pharmaceuticals, healthcare services, and healthcare information technology. The firm, founded in 1999, consists of a seasoned team of 12 managing directors with more than 130 years of venture capital investing experience and more than 150 years of operating experience. Versant Ventures currently manages in excess of $1.6 billion in committed capital and a portfolio of more than 75 companies.
5AM Ventures is an early-stage venture capital firm focused on building next-generation life sciences companies. Founded in 2002, 5AM Ventures has more than $390 million under management and is actively investing its third fund, 5AM Ventures III. The firm has offices in Menlo Park, CA and Waltham, MA.’
Sofinnova Partners is an independent venture capital firm based in Paris that invests in early-stage companies, corporate spin-offs, and turnaround situations in the technology and life sciences spaces, including cleantech. Sofinnova has financed 460 companies in Europe since 1972. Of those, more than 20% have gone public, more than 20% have been acquired, and, on average, revenues have multiplied eight times between financing and exit.
Pfizer Venture Investments
Pfizer Venture Investments (PVI), the venture capital arm of Pfizer, Inc., was founded in 2004 and invests for return in areas of current or future strategic interest to Pfizer. As part of the Worldwide Business Development, Strategy, and Innovation division, PVI seeks to remain at the forefront of life sciences advances, looking to identify and invest in emerging companies that are developing compounds and technologies that have the potential to enhance Pfizer’s pipeline and shape the future of the pharmaceutical industry. PVI invests in companies at any stage of development, with a strong focus on growth-stage opportunities, and is actively seeking to make new investments in a broad array of healthcare-related areas, including therapeutics, platform technologies, diagnostics, drug delivery, pharmaceutical services, healthcare IT, and other technologies impacting drug discovery and development.
Novo A/S is an active and independent company in its support of biotech ventures. The aspiration is to bring together the best of both worlds: industry insight and network from our pharma/biotech inheritance combined with a venture capital mindset that focuses on results and value creation.